Rep. Steve Cohen Sells Emergent BioSolutions Inc. (NYSE:EBS) Stock

Representative Steve Cohen (D-Tennessee) recently sold shares of Emergent BioSolutions Inc. (NYSE:EBS). In a filing disclosed on January 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Emergent BioSolutions stock on December 11th. The trade occurred in the Representative’s “STEPHENS SEP IRA” account.

Representative Steve Cohen also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Host Hotels & Resorts (NASDAQ:HST) on 12/11/2024.

Emergent BioSolutions Stock Up 0.9 %

Shares of NYSE EBS traded up $0.08 during mid-day trading on Wednesday, hitting $9.44. The company had a trading volume of 259,687 shares, compared to its average volume of 921,688. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The firm has a 50-day simple moving average of $9.36 and a two-hundred day simple moving average of $9.17. The company has a market capitalization of $511.50 million, a PE ratio of -2.30 and a beta of 1.60. Emergent BioSolutions Inc. has a one year low of $1.42 and a one year high of $15.10.

Institutional Investors Weigh In On Emergent BioSolutions

Institutional investors have recently modified their holdings of the business. Federated Hermes Inc. raised its stake in Emergent BioSolutions by 1,314.0% in the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock worth $1,864,000 after purchasing an additional 253,960 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Emergent BioSolutions in the third quarter valued at approximately $1,547,000. Headlands Technologies LLC acquired a new position in Emergent BioSolutions in the 2nd quarter valued at $969,000. Oak Hill Advisors LP acquired a new stake in shares of Emergent BioSolutions during the 3rd quarter worth $9,296,000. Finally, Assenagon Asset Management S.A. lifted its position in Emergent BioSolutions by 74.5% during the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after purchasing an additional 316,700 shares during the period. Institutional investors own 78.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on EBS shares. StockNews.com upgraded Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Tuesday. Benchmark upped their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a research note on Friday, January 10th.

About Representative Cohen

Steve Cohen (Democratic Party) is a member of the U.S. House, representing Tennessee’s 9th Congressional District. He assumed office on January 3, 2007. His current term ends on January 3, 2025. Cohen (Democratic Party) is running for re-election to the U.S. House to represent Tennessee’s 9th Congressional District. He declared candidacy for the Democratic primary scheduled on August 1, 2024. He represented District 30 of the Tennessee State Senate from 1983-2006. As a child, Cohen contracted polio. Cohen filed to run for his first elected office the same day that he first registered to vote. Cohen earned a bachelor’s degree from Vanderbilt and a J.D. from the University of Memphis School of Law. Prior to his election to the U.S. House, Cohen was a member of the Tennessee State Senate.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.